Smit A J, Van der Laan S, De Monchy J, Kallenberg C G, Donker A J
Clin Allergy. 1984 Sep;14(5):413-9. doi: 10.1111/j.1365-2222.1984.tb02224.x.
Cutaneous reactions associated with captopril treatment occurred in fifteen out of eighty-nine patients (17%). Dose reduction invariably led to improvement of the reaction but later recurrences were frequent (six patients). In four out of the fifteen patients captopril withdrawal ultimately was necessary. Skin tests and in vitro lymphocyte transformation tests with captopril were performed in these fifteen patients and also in nine captopril-treated control patients without adverse reactions. Positive epicutaneous skin tests were observed in five out of the fifteen patients including the four in whom captopril had to be withdrawn, but in none of the controls. Intracutaneous skin tests were positive in ten of the patients with cutaneous reactions and in two control patients. Captopril-induced in vitro lymphocyte transformation occurred in most patients with cutaneous reactions whereas in control patients captopril suppressed the in vitro lymphocyte proliferative response. Skin biopsies revealed histologic changes consistent with lymphocytic vasculitis. We conclude that epicutaneous skin tests with captopril are helpful in predicting the necessity of captopril withdrawal.
89名患者中有15名(17%)出现了与卡托普利治疗相关的皮肤反应。减少剂量总能使反应得到改善,但随后复发很常见(6名患者)。15名患者中有4名最终不得不停用卡托普利。对这15名患者以及9名接受卡托普利治疗但无不良反应的对照患者进行了卡托普利皮肤试验和体外淋巴细胞转化试验。15名患者中有5名皮试呈阳性,包括4名不得不停用卡托普利的患者,但对照患者中无一例阳性。10名有皮肤反应的患者和2名对照患者的皮内试验呈阳性。大多数有皮肤反应的患者出现了卡托普利诱导的体外淋巴细胞转化,而对照患者中卡托普利抑制了体外淋巴细胞增殖反应。皮肤活检显示组织学变化符合淋巴细胞性血管炎。我们得出结论,卡托普利皮试有助于预测停用卡托普利的必要性。